Ouro Medicines, a pioneering biotech company based in San Francisco, is thrilled to announce a remarkable funding round, successfully securing $120 million to advance its innovative research and development in immune reset therapeutics. Focused on transforming the landscape of treatment for chronic immune-mediated diseases, Ouro Medicines leverages cutting-edge T cell engagers to specifically target B cell-mediated conditions. This groundbreaking approach aims to induce immune resets, allowing patients to achieve long-term remission without the need for continuous immunosuppression, thereby significantly improving their quality of life. Established through a collaborative effort between Monograph Capital and GSK, Ouro Medicines has garnered support from a robust consortium of leading investors, including TPG, NEA, and Norwest. The newly raised funds will be instrumental in accelerating the company's clinical trials and expanding its therapeutic pipeline, with the ultimate goal of bringing new, safe, and effective therapies to patients in need. As healthcare professionals increasingly seek innovative solutions to manage complex immune disorders, Ouro Medicines is positioning itself at the forefront of a paradigm shift in treatment options, underscoring its commitment to enhancing patient outcomes through science-driven advancements. With the support of its talented team and strategic partners, Ouro is set to forge new pathways in immunology that promise to redefine the future of healthcare for countless individuals challenged by chronic diseases.
Ouro Medicines Secures $120 Million in Series A Funding to Revolutionize Treatment for Chronic Immune-Mediated Diseases
Recently funded · $120.0M Series aBiotechnology Research
Get the full Ouro Medicines company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)